Praglandia s.r.o.

The medical center is at the forefront of research in Type 2 Diabetes and related metabolic disorders, focusing on innovative treatments that address both obesity and cardiovascular diseases. The center's work in this area aims to improve patient outcomes by exploring alternatives to traditional insulin therapies.

• Type 2 Diabetes
• Cardiovascular Diseases
• Obesity and Overweight
• Chronic Kidney Disease

Through its research, the center contributes to the development of therapies that are not only effective but also enhance the quality of life for patients with complex metabolic conditions.

Specializing in atopic dermatitis and other skin conditions, the center is pioneering studies that evaluate the efficacy and safety of novel treatments. This includes the use of advanced biologics and other therapeutic agents to manage moderate-to-severe cases.

• Atopic Dermatitis
• Alopecia Areata

The center's research efforts are instrumental in developing new standards of care for dermatological conditions, offering hope for improved management and patient satisfaction.

Focusing on migraine management, the center is engaged in cutting-edge research to find effective preventive treatments for patients who have not responded to existing therapies. This includes exploring new pharmacological options that aim to reduce the frequency and severity of migraine episodes.

• Migraine

By advancing the understanding of migraine pathophysiology, the center is paving the way for innovative solutions that can significantly improve the lives of those affected by this debilitating condition.

The center is dedicated to enhancing the treatment of Major Depressive Disorder through research on adjunctive therapies. By investigating the long-term safety and efficacy of novel antidepressant combinations, the center aims to provide more effective treatment options for patients with treatment-resistant depression.

• Major Depressive Disorder

These efforts are crucial in addressing the unmet needs in mental health care, offering new hope for individuals struggling with persistent depressive symptoms.